Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFG-02 Transdermal Formulation in Healthy Japanese and White Participants
NCT07167914Phase 1Completed
- Sponsor
- Juro Sciences
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of SFG-02 (4 arms), sponsored by Juro Sciences. Primary endpoints: Safety and Tolerability at 14 days, Maximum concentration at 7 days and 3 more. Started Sep 2025; status: completed.
02
Drugs
SFG-02
Beyond the preview
Go deeper on NCT07167914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07167914.